Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

ConclusionsWithin the limitations of this network meta-analysis, the comparison indicates that CDK4/6is plus AIs might represent a better option for HR+  ABC as a first-line endocrine treatment compared with fulvestrant.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research